PMID- 35730239
OWN - NLM
STAT- MEDLINE
DCOM- 20230327
LR  - 20230331
IS  - 1532-4303 (Electronic)
IS  - 0277-0903 (Linking)
VI  - 60
IP  - 4
DP  - 2023 Apr
TI  - The assessment of effectiveness, tolerance, and patient satisfaction with the use 
      of a new fixed-dose combination product, containing salmeterol and fluticasone 
      propionate, Salflumix Easyhaler(R) in the treatment of asthma in the daily clinical 
      practice.
PG  - 754-760
LID - 10.1080/02770903.2022.2093220 [doi]
AB  - BACKGROUND: The effectiveness of a fix-dose salmeterol/fluticasone combination 
      therapy in asthma was previously shown for the original product. The study aim 
      was to evaluate the clinical effectiveness and safety of a second entry DPI - dry 
      powder inhaler (Salflumix Easyhaler) in patients with asthma in everyday clinical 
      practice. PATIENTS AND METHODS: This multicenter Investigator-Initiated Study 
      that enrolled 2,037 adult outpatients with asthma treated with Salflumix 
      Easyhaler, was conducted by 220 pulmonologists across Poland. Asthma control was 
      assessed during 3 visits with 6 +/- 2 weeks intervals based on the Asthma Control 
      Test (ACT). In addition, patient Satisfaction with Asthma Treatment Questionnaire 
      (SATQ) and adherence and adverse events (AEs) were monitored. RESULTS: During the 
      observation (86 +/- 30 days) the percentage of patients with controlled asthma (ACT 
      20-25 pts) increased from 35.5% at the first visit to 86.5% at the third visit 
      (p < 0.001). In the subgroup analysis, there were more patients not obtaining 
      asthma control among patients that switched from the treatment with other devices 
      than in naive ones. Global SATQ scores increased from 5.8 +/- 0.7 to 6.2 +/- 0.6 
      during the observation. Patients' satisfaction with the use of the Salflumix 
      Easyhaler was high. Adherence exceeded 95%. Eight AEs were reported. CONCLUSIONS: 
      Salflumix Easyhaler is highly effective and well-tolerated by naive patients with 
      asthma and those switching from another device. In general, patients show good 
      compliance with medical product and are satisfied with the use of this new 
      device, and not reporting difficulties and errors related to its' use. Their 
      physicians' overall perception of Salflumix Easyhaler use is very positive.
FAU - Doniec, Zbigniew
AU  - Doniec Z
AUID- ORCID: 0000-0003-3896-1053
AD  - Department of Pneumonology, Institute of Tuberculosis and Lung Diseases, 
      Rabka-Zdroj, Poland.
FAU - Olszanecka-Glinianowicz, Magdalena
AU  - Olszanecka-Glinianowicz M
AUID- ORCID: 0000-0001-5632-5590
AD  - Health Promotion and Obesity Management Unit, Department of Pathophysiology, 
      Faculty of Medical Sciences in Katowice, Medical University of Silesia, Katowice, 
      Poland.
FAU - Hantulik, Piotr
AU  - Hantulik P
AUID- ORCID: 0000-0001-5088-5204
AD  - Orion Pharma Poland Co. Ltd, Warszawa, Poland.
FAU - Almgren-Rachtan, Agnieszka
AU  - Almgren-Rachtan A
AUID- ORCID: 0000-0002-6766-8123
AD  - Euromedic Medical Centre, Katowice, Poland.
FAU - Chudek, Jerzy
AU  - Chudek J
AUID- ORCID: 0000-0002-6367-7794
AD  - Pathophysiology Unit, Department of Internal Diseases and Oncological 
      Chemotherapy, Faculty of Medical Sciences in Katowice, Medical University of 
      Silesia, Katowice, Poland.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20220630
PL  - England
TA  - J Asthma
JT  - The Journal of asthma : official journal of the Association for the Care of 
      Asthma
JID - 8106454
RN  - CUT2W21N7U (Fluticasone)
RN  - 6EW8Q962A5 (Salmeterol Xinafoate)
RN  - 0 (Fluticasone-Salmeterol Drug Combination)
RN  - 0 (Bronchodilator Agents)
RN  - 0 (Androstadienes)
RN  - QF8SVZ843E (Albuterol)
SB  - IM
MH  - Adult
MH  - Humans
MH  - *Asthma/drug therapy/chemically induced
MH  - Fluticasone/adverse effects
MH  - Salmeterol Xinafoate
MH  - Patient Satisfaction
MH  - Fluticasone-Salmeterol Drug Combination/therapeutic use
MH  - Treatment Outcome
MH  - Bronchodilator Agents/adverse effects
MH  - Androstadienes/adverse effects
MH  - Albuterol
OTO - NOTNLM
OT  - asthma
OT  - fix-dose salmeterol/fluticasone combination therapy
OT  - patients satisfaction
OT  - real-life data
EDAT- 2022/06/23 06:00
MHDA- 2023/03/28 06:00
CRDT- 2022/06/22 03:43
PHST- 2022/06/23 06:00 [pubmed]
PHST- 2023/03/28 06:00 [medline]
PHST- 2022/06/22 03:43 [entrez]
AID - 10.1080/02770903.2022.2093220 [doi]
PST - ppublish
SO  - J Asthma. 2023 Apr;60(4):754-760. doi: 10.1080/02770903.2022.2093220. Epub 2022 
      Jun 30.